R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The funding will accelerate Sinopia’s data-driven drug discovery efforts
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated
